ArticleBMC microbiology2026
A one-pot CRISPR/Cas12b assay for extraction-free and visual detection of Haemophilus influenzae.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Haemophilus influenzae is a major respiratory pathogen, particularly in pediatric populations, and its rapid and accurate detection is critical for early diagnosis and targeted treatment. Traditional diagnostic methods, such as bacterial culture and PCR, are often time-consuming and require specialized equipment. In this study, we developed the Hi-ExCad assay, a one-pot, extraction-free CRISPR/Cas12b-based system for the rapid, simple, and accurate detection of H. influenzae. The assay integrates loop-mediated isothermal amplification and CRISPR/Cas12b detection in a single reaction, enabling direct detection from clinical sputum samples without the need for nucleic acid extraction. The Hi-ExCad assay demonstrated high specificity, correctly identifying H. influenzae in clinical samples, with a limit of detection of 1 pg of genomic DNA. The assay also exhibited excellent performance in real-time detection and visual result interpretation under blue light, making it highly suitable for point-of-care testing and resource-limited settings. These findings suggest that the Hi-ExCad assay provides a rapid, reliable, and user-friendly method for the detection of H. influenzae, with significant potential for clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.